肿瘤细胞治疗研究
英文原题：Gene Targets of CAR-T Cell Therapy for Glioblastoma.
胶质母细胞瘤（GBM）是一种侵袭性原发性脑肿瘤，常规治疗干预后预后较差。
胶质母细胞瘤（GBM）是一种侵袭性原发性脑肿瘤，常规治疗干预后预后较差。此外，血脑屏障（BBB）严重阻碍化疗药物的渗透，从而降低其疗效。因此，开发新的GBM治疗方法至关重要。一种新型的周细胞免疫疗法称为CAR-T（CAR-T）细胞治疗，利用CAR-T细胞靶向并摧毁肿瘤细胞，无需抗原辅助，具有高度特异性，且不受主要组织相容性复合体（MHC）限制。它已成为最有前景的治疗技术之一，在血液系统恶性肿瘤，特别是白血病中取得了积极的临床结果。由于其在血液系统恶性肿瘤中的疗效，CAR-T细胞疗法有可能治疗实体瘤，包括GBM。另一方面，CAR-T细胞治疗在治疗GBM方面的疗效不如在治疗其他血液系统恶性肿瘤中那样显著。CAR-T细胞治疗GBM面临若干挑战。本文综述了CAR-T细胞疗法在血液系统肿瘤中的应用以及在GBM中的靶点选择、困难和挑战。
Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood-brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop novel GBM treatment methods. A novel kind of pericyte immunotherapy known as chimeric antigen receptor T (CAR-T) cell treatment uses CAR-T cells to target and destroy tumor cells without the aid of the antigen with great specificity and in a manner that is not major histocompatibility complex (MHC)-restricted. It has emerged as one of the most promising therapy techniques with positive clinical outcomes in hematological cancers, particularly leukemia. Due to its efficacy in hematologic cancers, CAR-T cell therapy could potentially treat solid tumors, including GBM. On the other hand, CAR-T cell treatment has not been as therapeutically effective in treating GBM as it has in treating other hematologic malignancies. CAR-T cell treatments for GBM have several challenges. This paper reviewed the use of CAR-T cell therapy in hematologic tumors and the selection of targets, difficulties, and challenges in GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
